A Phase I randomised, open-label, two-period crossover study of CK 2127107 in healthy male volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2014
At a glance
- Drugs CK 2127107 (Primary)
- Indications Muscular atrophy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Astellas Pharma
- 13 Oct 2014 Status changed from recruiting to completed, according to a Cytokinetics media release.
- 13 Oct 2014 Results published in the Media Release.
- 18 Mar 2014 New trial record